172@29@17@102!~!172@29@0@53!~!|news|tags|gilead-sciences-inc.html|news|!~!|controller|tag.php
gilead sciences inc
Jump to
8 Results Found
  • Gilead says additional data on remdesivir shows improved clinical recovery Jul 10, 2020 06:46 PM IST

    Gilead says additional data on remdesivir shows improved clinical recovery

    Findings from an analysis of its late-stage study showed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percent of patients receiving standard of care, the company said.

  • Gilead's remdesivir shows promise in COVID-19 study on monkeys Jun 09, 2020 06:52 PM IST

    Gilead's remdesivir shows promise in COVID-19 study on monkeys

    Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies is being closely watched as nations look for a treatment for the disease, which has infected more than 7 million people and killed over 400,000.

  • Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions Jun 02, 2020 04:46 PM IST

    Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions

    Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better.

  • Gilead says remdesivir helped moderate COVID-19 patients improve Jun 01, 2020 06:58 PM IST

    Gilead says remdesivir helped moderate COVID-19 patients improve

    At Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, Gilead said.

  • Strides Arcolab launches generic version of Sofosbuvir Mar 27, 2015 09:15 PM IST

    Strides Arcolab launches generic version of Sofosbuvir

    Sofosbuvir has high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions, which makes it a breakthrough drug in Hepatitis C treatment.

  • Dr Reddy's to launch Hepatitis C drug in India Mar 23, 2015 06:49 PM IST

    Dr Reddy's to launch Hepatitis C drug in India

    Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

  • Natco Pharma ties up with Gilead on hepatitis C drugs Mar 02, 2015 01:35 PM IST

    Natco Pharma ties up with Gilead on hepatitis C drugs

    Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.

  • Gilead signs deals with Indian cos for low-cost HIV drug Aug 02, 2012 07:26 PM IST

    Gilead signs deals with Indian cos for low-cost HIV drug

    Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.

Sections